Rare Disease Day 2020 will be celebrated this year on Saturday the 29th of February - a fittingly rare date! Coordinated by EURORDIS in partnership with National Alliances, the aim is to raise awareness amongst the general public and decision-makers about rare diseases and their impact on patients' lives. Lead-up events throughout the month will be organised by members of the rare disease community including patient organisations, healthcare professionals, researchers, and policymakers across 101 countries.

Rare diseases will affect 1 in 20 people in their lifetime, but their rarity often leads to delays in diagnosis, and means that information and treatment options can be limited. Rare Disease Day is an opportunity to strengthen international cooperation, vital for identifying and classifying these diseases, coordinating research, and providing access to treatment and support for patients, their families, and carers.

For more information, go to the Rare Disease Day 2020 website.

 

The European Rare Disease Models & Mechanisms Network (RDMM-Europe) has been established by Solve-RD – an EU-funded research project. The overall aim is to boost research in rare diseases, discover new disease-causing genes and obtain evidence for pathogenicity through functional validation.

For more information, visit the following website.

EATRIS Services for E-RARE 3 call

EATRIS Services for E-RARE 3 call

EATRIS ERIC, the European Infrastructure for Translational Medicine, specialises in advancing medicines safely into clinical development. With over 75 leading academic translational research institutions across Europe, EATRIS can find your partner with specialised facilities and long-standing expertise in an array of disciplines, including:

  • In vivo imaging-enabled drug development, supporting pre-clinical and clinical assessment of target expression, modulation and internalisation, drug pharmacokinetics and biodistribution, normal organ uptake, optimisation of drug dose & scheduling, and assessment of inter-patient variation;
  • Drug (re-) formulation expertise, access to an array of drug delivery technologies;
  • Access to a wide array of specialised pre-clinical models, as well as clinical expertise and patient cohorts for many rare diseases.

Please email Florence Bietrix for more information [florencebietrix[at]eatris.eu] or check EATRIS website

E-Rare 2012 - Created by Toussaint Biger